Analysis assays cannot be approved. The only test that is approved by the US Food and Drug Administration and the European Medicines Agency is the Cellsearch test. The way we analyse circulating tumour cells is certified for accuracy.

You can find the data we have published and presented at medical conferences here.

This depends on the cancer. With the exception of the Oncotrace test, every RGCC test can be conducted with just a blood sample. Certain cancers – for example, glioblastoma and other types of brain cancer – require both a blood and a tissue sample for tests.

These tests are for all solid and blood tumour malignancies, with the exception of primary tumours of the central nervous system.

We calculate the number of circulating tumour cells from the total amount of blood cells, expressed as the volume of circulating tumour cells per millilitre of blood. This cannot be calculated from a tissue sample. To conduct a circulating tumour cell test, a blood sample must be provided.

The tissue sample taken from the tumour during a biopsy is part of the tumour contain cancerous cells, so there is no need to search for CTC populations.

Yes, but a patient must wait seven days after chemotherapy treatment before taking the test.

The Onconomics and Onconomics Plus tests look for the expression of genes that are linked with the effect of specific drugs on the cancer cells in a single patient.

The comparative genetic hybridisation (CGH) test provides information about genetic abnormalities present in tumour cells that can be associated with tumours. This test is relatively new and we do not yet provide it at RGCC.

The ChemoSNiP test can be used to predict whether a patient will have a good or bad response to a drug, or no response at all.

We recommend the Onconomics or Onconomics Plus tests.